| 76.12 1.89 (2.55%) | 07-17 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 92.5 |
1-year : | 108.04 |
| Resists | First : | 79.19 |
Second : | 92.5 |
| Pivot price | 71.51 |
|||
| Supports | First : | 65.15 |
Second : | 56.47 |
| MAs | MA(5) : | 75.24 |
MA(20) : | 69.59 |
| MA(100) : | 77.24 |
MA(250) : | 68.26 |
|
| MACD | MACD : | 1.3 |
Signal : | 0 |
| %K %D | K(14,3) : | 77.7 |
D(3) : | 76.7 |
| RSI | RSI(14): 57.3 |
|||
| 52-week | High : | 123.75 | Low : | 25.56 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ DRUG ] has closed below upper band by 24.8%. Bollinger Bands are 0.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 79.27 - 79.83 | 79.83 - 80.26 |
| Low: | 72.12 - 72.68 | 72.68 - 73.12 |
| Close: | 75.37 - 76.26 | 76.26 - 76.95 |
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company’s BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.
Fri, 17 Jul 2026
Bright Minds Biosciences (NASDAQ:DRUG) Shares Up 5% - Should You Buy? - MarketBeat
Fri, 10 Jul 2026
Bright Minds Biosciences (NASDAQ:DRUG) Shares Down 7.7% - What's Next? - MarketBeat
Sat, 27 Jun 2026
DRUG Forecast — Price Target — Prediction for 2027 - TradingView
Thu, 21 May 2026
Why a $5 Million New Position Signals Confidence in This Epilepsy Drug Pipeline - The Motley Fool
Wed, 25 Mar 2026
What Is the Probability of Success for Bright Minds Biosciences Inc (DRUG)’s Lead Drug Candidate? - Yahoo Finance
Fri, 09 Jan 2026
Bright Minds Biosciences closes $175 million public offering - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 10 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 12 (%) |
| Held by Institutions | 92.9 (%) |
| Shares Short | 953 (K) |
| Shares Short P.Month | 806 (K) |
| EPS | -2.42 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 22.19 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -10.5 % |
| Return on Equity (ttm) | -15.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -20 (M) |
| Levered Free Cash Flow | -13 (M) |
| PE Ratio | -31.59 |
| PEG Ratio | 0 |
| Price to Book value | 3.43 |
| Price to Sales | 0 |
| Price to Cash Flow | -37.66 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|